Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
PNH first pivotal read-out for iptacopan "pipeline in a pill" with
combined multi-blockbuster potential
Indication
2021
2022
2023
2024
2025
2026
PNH
IgAN
*
C3G
aHUS
IC-MPGN
Phase 3 studies initiated or planned
9 months readout may support US submission for accelerated approval
Multi-blockbuster potential across indications
3
INNOVATION
Paroxysmal nocturnal hemoglobinuria
(PNH) Phase 3 trials
APPLY-PNH
both primary endpoints of superiority
vs. anti-C5 antibody met
APPOINT-PNH
in patients naive to anti-C5 antibody
therapy expected to read out in 2022
IgAN - IgA nephropathy C3G C3 glomerulopathy IC-MPGN - Immune Complex Membranoproliferative glomerulonephritis aHUS atypical hemolytic uremic syndrome PNH - paroxysmal nocturnal hemoglobinuria
16 Investor Relations | Q3 2022 Results
ā NOVARTIS | Reimagining MedicineView entire presentation